Arrae GLP-1 ("Faux-Zempic") Review: What the "15 Trials" Actually Show

Arrae's MB-1 is one of the most aggressively marketed products in the entire "natural GLP-1" category. It is sold to women as a daily metabolism capsule, framed as a "natural Faux-Zempic," and the pitch leans on two numbers that show up everywhere in the ads: it is "backed by 15 clinical trials" across its ingredients, and "over 357,000 women" have switched to it. Those figures are doing an enormous amount of persuasive work. So we did what we do with every product on this site: we set the marketing aside, read what is actually in the bottle, and checked what those "15 trials" actually measured. The gap between the framing and the evidence is the entire story here.

Here is the short version, stated plainly so no one can miss it: Arrae MB-1 contains no GLP-1 drug, no semaglutide, no tirzepatide, and no prescription medicine of any kind. It is a seven-ingredient botanical-and-mineral capsule, and there is no published clinical trial of the finished MB-1 product. The "15 trials" are studies of the individual ingredients — run in different people, at different doses, with different (and often modest) results — not a trial of the thing you would actually swallow. "Faux-Zempic" is a marketing phrase, not a pharmacological claim, and a UK advertising regulator has already ruled the comparison misleading.

What's actually in the bottle

MB-1 is built on seven inputs: African mango (Irvingia gabonensis) seed extract, Cissus quadrangularis extract, grains of paradise (Aframomum melegueta), the probiotic Bifidobacterium animalis subsp. lactis 420 (B420), green tea extract, vitamin B6, and chromium picolinate. None of these is exotic — each is a familiar weight-management supplement ingredient that has been sold on its own for years. The important question is not whether they have any studies (several do), but whether those studies support the drug-adjacent promise the name implies, and whether MB-1 delivers each ingredient at the dose that was actually tested.

African mango (Irvingia gabonensis). This is the ingredient that anchors the dramatic numbers. A frequently-cited randomized, double-blind, placebo-controlled trial of a standardized seed extract (IGOB131) reported a large body-weight reduction versus placebo over ten weeks¹ — the source of the eye-catching figures in the marketing. But the honest reading requires the next sentence: an independent systematic review of the Irvingia gabonensis randomized trials concluded the studies were of poor methodological quality and that the evidence was too weak to support a firm weight-loss claim². A single dramatic trial that a systematic review then flags as low-quality is exactly the kind of result that should be quoted with caution, not as a headline.

Green tea extract. Green tea catechins plus caffeine have a real but small thermogenic effect. A meta-analysis of green-tea trials found a statistically significant but modest effect on body weight and weight maintenance³ — on the order of a kilogram or so, and dependent on getting a meaningful catechin dose. We cover exactly how thin and dose-dependent that effect is in our green tea extract for weight loss review.

Chromium picolinate. Chromium is one of the most-studied weight-loss minerals, and the verdict is settled and unimpressive: a Cochrane review of chromium picolinate in overweight and obese adults found only a very small effect on body weight, of uncertain clinical relevance⁴. More detail is in our chromium picolinate for weight loss breakdown.

Grains of paradise. Aframomum melegueta has a genuinely interesting mechanism study: a small trial in men found the extract activated brown adipose tissue and increased whole-body energy expenditure⁵. But "increased energy expenditure" here means roughly a few dozen extra calories burned — a mechanism signal, not a demonstrated weight-loss outcome.

B420 probiotic. B. lactis 420 is the ingredient closest to a real "GLP-1-adjacent" story, and even it is indirect. A randomized controlled trial reported that B420 (with or without fiber) controlled body-fat mass in overweight and obese adults versus control⁶, and a later randomized trial of a B420-containing synbiotic reported shifts in the gut microbiome and metabolism during weight management⁷. These are real results — but they are fat-mass and microbiome effects from probiotic trials, not evidence that MB-1 raises GLP-1 to anything like a drug effect.

Cissus quadrangularis and vitamin B6 round out the formula; Cissus has only mixed, inconsistent trial evidence, and B6 is a routine vitamin with no weight-loss effect on its own.

Why "15 trials / 357,000 women" is not what it sounds like

Read the two headline numbers literally and the problem is obvious. "Backed by 15 clinical trials" does not mean fifteen trials of MB-1 — it means the seven ingredients, summed together, have about fifteen studies between them. Those trials used different doses, different populations, and in several cases reported only small or inconsistent effects. Stacking seven ingredients into one capsule does not stack their trial results; you cannot add up effect sizes from separate studies of separate compounds and claim the total for a product that has never been tested as a whole. There is no published clinical trial of the finished MB-1 formula. "Each ingredient has a study" and "this product is proven" are completely different claims, and only the first one is true.

The "357,000 women" figure is a sales-volume / customer-count number, not a research finding at all. It tells you the product sells well. It tells you nothing about whether it works, because satisfied-customer counts are not a clinical endpoint and carry no placebo control.

There is also a dosing problem that the "15 trials" framing quietly papers over. The African mango trial used a specific standardized IGOB131 dose¹; the green tea effect depends on hitting a real catechin dose³; the chromium and grains-of-paradise effects are tiny even at studied doses⁴⁵. A seven-ingredient capsule has limited room, and unless MB-1 delivers each active at its studied dose, even the modest ingredient-level effects may not carry over. "Contains the ingredient from a study" is not the same as "contains the dose that produced the result."

"Faux-Zempic" is a name, not an effect size

The most important caveat is the one the marketing works hardest to blur. MB-1 is positioned as a "natural Faux-Zempic" — a stand-in for Ozempic — but nothing in its evidence base resembles what a GLP-1 drug does. The pivotal STEP 1 trial of semaglutide produced about 15% mean body-weight loss over 68 weeks by saturating the GLP-1 receptor at supraphysiologic levels⁸. MB-1's strongest ingredient signals are a single low-quality African-mango trial¹², a roughly one-kilogram green-tea effect³, a near-negligible chromium effect⁴, a few-dozen-calorie thermogenic nudge⁵, and a probiotic fat-mass result⁶. That is not a smaller version of a GLP-1 drug — it is a different category of intervention entirely.

This is not just our editorial opinion. In 2025 the UK's Advertising Standards Authority upheld a ruling against Arrae's MB-1 advertising, finding that consumers were likely to understand the "Faux-Zempic" framing to mean the product had effects equivalent to Ozempic, that the ads made unauthorized medicinal and health claims, and that referencing a specific rate of weight loss ("achieve my goal weight in three months") breached the rules for food supplements. A regulator looked at the same marketing we did and reached the same conclusion: the comparison oversells what the product can do.

What the evidence does and doesn't support

None of this makes MB-1 a scam in the sense of containing nothing. The ingredients are real, a few have legitimate (if modest) human data, and B420 and green tea are reasonable supplement choices on their own merits. The problem is purely magnitude and framing. The product borrows the name of a medication class that works an order of magnitude more powerfully, presents a customer-count number and a summed ingredient-trial count as if they were proof of the finished product, and leans on a single low-quality trial for its most dramatic figure. The honest grade for "MB-1 is comparable to a prescription GLP-1 drug" is no evidence — and "MB-1 the finished product causes meaningful weight loss" has no good data either, because that trial does not exist. This is the exact pattern we flag across the category in our GLP-1 booster supplements review and our do GLP-1 supplements work? explainer.

How to think about buying it

As of 2026 Arrae MB-1 sells in the premium range typical of the category — roughly $50–$70 for a one-month supply, less on subscription — which makes the evidence question a real one for your budget. If you want to try it, set expectations to match the data rather than the name: treat it as a mild, ingredient-level metabolism support layered on top of diet, protein, fiber and sleep, and treat any scale movement as a modest bonus rather than the engine of weight loss. What you should not do is buy it expecting it to stand in for, or work like, a prescription GLP-1. If meaningful, drug-like weight loss is the goal, the honest magnitude comparison is laid out in our supplements vs GLP-1 drugs breakdown, and the gap is roughly an order of magnitude.

The bottom line

Arrae MB-1 is a premium-priced, seven-ingredient supplement marketed with two numbers — "15 clinical trials" and "357,000 women" — that sound like proof and are not. The trials belong to the individual ingredients, not to MB-1, which has never been tested as a finished product; the customer count is a sales figure, not a clinical result. Its ingredient evidence ranges from a single low-quality African-mango trial to a modest green-tea effect to a near-negligible chromium effect, none of it close to a GLP-1 drug — a comparison a UK regulator has already ruled misleading. For where this lands among everything we have vetted, see our best natural GLP-1 supplements guide, and for the full category framework, start with our pillar, 'natural GLP-1' supplements: what the evidence shows.